Icotrokinra Demonstrated Long-Term Ulcerative Colitis Success
A clinical trial extension showed sustained patient response and treatment retention through 76 weeks.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Do you trust that new oral drugs are as effective as traditional intravenous treatments?
An extension of the ANTHEM-UC trial revealed that the drug icotrokinra, a targeted oral peptide, maintained clinical response and remission in most ulcerative colitis patients through week 76. Approximately 87% of study participants remained on the treatment through week 78.
Why it matters
The findings suggest that the IL-23 receptor blocker could be positioned for early use in treating ulcerative colitis. Achieving long-term remission while remaining corticosteroid-free remains a primary goal for managing the chronic inflammatory condition.
Most of the 136 trial participants achieved clinical response, remission, and endoscopic improvement, with 97% of those in remission remaining corticosteroid-free. One case of ductal carcinoma in situ was reported in the 100-mg dose group.
The players
US Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.
The details
Researchers evaluated the oral peptide across 100 mg, 200 mg, and 400 mg doses, with those showing inadequate response at week 16 receiving adjustments. The study utilized nonresponder imputation to assess results, confirming that the treatment effectively targets the interleukin-23 receptor.
Timeline
March 2026: FDA approved icotrokinra for plaque psoriasis.
Week 76: Evaluation point for clinical response and remission.
Week 78: Final safety visit and treatment retention recorded.
October 9-14, 2026: Results presented at the ACG meeting in Nashville.
Health Landscape
This research follows the ongoing ANTHEM-UC trial, which marks a significant progression in the development of targeted oral peptides for chronic inflammatory diseases. These results expand the clinical understanding of IL-23 receptor blockers beyond their initial approval for plaque psoriasis.
Patients may eventually gain access to an oral treatment option that potentially reduces the need for long-term corticosteroid use. The drug, which is already FDA-approved for plaque psoriasis, is being evaluated to offer a more convenient route for those managing chronic bowel inflammation.
The takeaway
These results highlight the potential for oral, targeted therapies to provide durable, corticosteroid-free relief for patients with chronic gastrointestinal conditions. Patients should consult with a gastroenterologist regarding the evolution of these clinical options and their eligibility for future clinical trials.
Further reading
For more information on current treatment trends, visit the Cancer section.
More information
Review the full findings in the J&J clinical study press release.
Live Poll
Do you trust that new oral drugs are as effective as traditional intravenous treatments?
